Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 2 patents
1 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI104257

INACTIVATION OF ENDOTOXIN BY A HUMORAL COMPONENT. VII. ENZYMATIC DEGRADATION OF ENDOTOXIN BY BLOOD PLASMA

Willis R. Keene, Maurice Landy, and Murray J. Shear

Laboratory of Chemical Pharmacology, National Cancer Institute, Bethesda, Md.

†

Present address: U. S. Public Health Service Hospital, Boston, Mass.

*

In previous reports it was convenient to use a brief, tentative designation (EDC) for the component in blood responsible for the detoxification of endotoxin in vitro. More recent studies in this Laboratory indicate that there may be more than one host enzyme capable of catalyzing this reaction; e.g., endotoxin can be inactivated in vitro by tissue homogenates under conditions which differ from those required for detoxification by blood (1, 2). In the present report, the host product employed as a source of endotoxin-inactivating enzyme is referred to, simply, as plasma or serum.

Find articles by Keene, W. in: PubMed | Google Scholar

Laboratory of Chemical Pharmacology, National Cancer Institute, Bethesda, Md.

†

Present address: U. S. Public Health Service Hospital, Boston, Mass.

*

In previous reports it was convenient to use a brief, tentative designation (EDC) for the component in blood responsible for the detoxification of endotoxin in vitro. More recent studies in this Laboratory indicate that there may be more than one host enzyme capable of catalyzing this reaction; e.g., endotoxin can be inactivated in vitro by tissue homogenates under conditions which differ from those required for detoxification by blood (1, 2). In the present report, the host product employed as a source of endotoxin-inactivating enzyme is referred to, simply, as plasma or serum.

Find articles by Landy, M. in: PubMed | Google Scholar

Laboratory of Chemical Pharmacology, National Cancer Institute, Bethesda, Md.

†

Present address: U. S. Public Health Service Hospital, Boston, Mass.

*

In previous reports it was convenient to use a brief, tentative designation (EDC) for the component in blood responsible for the detoxification of endotoxin in vitro. More recent studies in this Laboratory indicate that there may be more than one host enzyme capable of catalyzing this reaction; e.g., endotoxin can be inactivated in vitro by tissue homogenates under conditions which differ from those required for detoxification by blood (1, 2). In the present report, the host product employed as a source of endotoxin-inactivating enzyme is referred to, simply, as plasma or serum.

Find articles by Shear, M. in: PubMed | Google Scholar

Published February 1, 1961 - More info

Published in Volume 40, Issue 2 on February 1, 1961
J Clin Invest. 1961;40(2):302–310. https://doi.org/10.1172/JCI104257.
© 1961 The American Society for Clinical Investigation
Published February 1, 1961 - Version history
View PDF
Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 302
page 302
icon of scanned page 303
page 303
icon of scanned page 304
page 304
icon of scanned page 305
page 305
icon of scanned page 306
page 306
icon of scanned page 307
page 307
icon of scanned page 308
page 308
icon of scanned page 309
page 309
icon of scanned page 310
page 310
Version history
  • Version 1 (February 1, 1961): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
1 readers on Mendeley
See more details